Antonio Marra

@AntonyMarra

M.D. - Medical Oncology Resident @ University of Milan - European Institute of Oncology

Milano, Lombardia
Vrijeme pridruživanja: svibanj 2011.

Tweetovi

Blokirali ste korisnika/cu @AntonyMarra

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AntonyMarra

  1. 20. sij

    Our latest review on pathogenesis and clinical management of breast implant-associated anaplastic large cell lymphoma just out on ➡️ Regular follow-up in women with textured implants ➡️ Multidisciplinary approach is essential

    Poništi
  2. proslijedio/la je Tweet
    14. sij

    Featured article this month is the Perspective from & Priti Hegde: "Top 10 Challenges in " | Discusses the top 10 challenges facing this field & what is necessary to overcome them

    Poništi
  3. proslijedio/la je Tweet
    13. sij

    Kudos to for thinking, managing and pushing thru the finish line our new work now out in Nat Gen. She is more than ready to run her lab. and more. Here is the link and a tweetorial

    Prikaži ovu nit
    Poništi
  4. proslijedio/la je Tweet
    8. sij

    Study presents an interactive CAR clinical trial database, spanning 64 targets in T cells, NK cells or mixtures of both, which suggests a landscape of >100 single targets and >100,000 possible target pairs using logical switches for CAR cell engineering:

    Poništi
  5. proslijedio/la je Tweet
    6. sij

    A guide for young residents! ⁦⁩ ⁦⁩ ⁦

    Poništi
  6. proslijedio/la je Tweet
    25. pro 2019.

    Is there an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Our work out for Christmas!

    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    3. pro 2019.

    BRCA1 mut, PD-L1 negative TNBC patient with liver mets, ECOG 0. Given the chance of internal 2nd line PARPi clinical trial, what’s your 1st line Tx choice?

    Poništi
  8. proslijedio/la je Tweet
    2. pro 2019.

    Top presentations : HER2Climb - tucatinib DESTINYbreast01 - DS8201 APHINITY- perjeta OS update ATEMPT - adjuvant TDM1 Two on adj capecitabine PEARL palbo/ET vs chemo Keynote522 / neoTRIPaPDL1 neoadj PD1/PDL1 in TNBC MRI vs mammo in FH pts RCB data oral taxane

    Poništi
  9. proslijedio/la je Tweet

    "We almost fell off our chairs." According to a new MSK study in by , Bob Li, and Jorge Reis-Filho, many mutations found in don’t come from tumor cells but from alterations in white blood cells.

    Poništi
  10. 30. lis 2019.

    PDL1 amplification can be detected in 0.7% of all solid tumors and is able to predict durable responses to anti-PD-1/PD-L1 even in absence of microsatellite instability, high PD-L1 expression and a high TMB

    Poništi
  11. 12. lis 2019.

    Nice and interesting work on the role of PTEN loss in cross-resistance to CDK4/6 and PI3Kα inhibitors in , suggesting potential and considerable implications for optimal treatment sequencing strategies in mBC

    Poništi
  12. proslijedio/la je Tweet

    With all the residents after exciting examinations, they are about to start 4th year (except Giovanni Fuca’ just back from UNC) young docs empowerment

    Poništi
  13. 30. ruj 2019.

    Interesting work just presented at and simultaneously published in - sTILs can identify a subgroup of stage I pts with excellent prognosis without adjuvant CT ⁦⁦

    Poništi
  14. proslijedio/la je Tweet
    28. ruj 2019.

    The and UNIMI team ready for the YOC party: a must-to after a full day of meetings and sessions started at 6 AM and finished...3 AM still ongoing!!! Who will pay Coffey for All, tomorrow?

    , , i još njih 2
    Poništi
  15. 29. ruj 2019.

    MONARCH-2 trial demonstrated statistically significant improvement in OS with the addiction of abemaciclib to fulvestrant in metastatic HR+ HER2- breast cancer

    Poništi
  16. 28. ruj 2019.

    New and proper biomarkers are definitely needed to better select TNBC patients for next-generation immunotherapy trials. Great and inspiring talk by on new frontiers in treatment

    Poništi
  17. 28. ruj 2019.

    monarchHER trial met its primary endpoint (PFS), suggesting a role for abemaciclib in combination with fulvestrant and trastuzumab in metastatic triple-positive breast cancer

    Poništi
  18. proslijedio/la je Tweet
    3. ruj 2019.

    ESMO Lifetime Achievement Award - Angelo Di Leo: for his outstanding career dedicated to research & education. An internationally renowned expert in who pioneered research & contributed signif 2 dev of personalised treatmt approaches

    Poništi
  19. 29. kol 2019.

    Are all CDK4/6 inhibitors created equal? | Just published on ⁦ our article on clinical and pharmacological differences of CDK4/6 inhibitors in breast cancer treatment ⁦⁩ ⁦

    Poništi
  20. proslijedio/la je Tweet
    3. kol 2019.

    Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·